Virbac Acquires Thyronorm to Combat Feline Hyperthyroidism

Virbac, a leading international veterinary company, has purchased Thyronorm, an innovative treatment for feline hyperthyroidism, from Norbrook. This acquisition, valued at approximately £100 million, aims to enhance the quality of life for senior cats suffering from this common endocrine disease. Thyronorm, a liquid medication preferred over tablets for precise dosing, will be distributed under the Thyronorm and Felanorm brands in various markets, with Virbac planning to expand its global reach over time.

Feline hyperthyroidism affects over 10% of older cats, causing serious health issues if not managed properly. The acquisition aligns with Virbac's portfolio and promises to be accretive to sales growth and EBITDA margins from the first year. Norbrook will remain the manufacturer, maintaining a strong partnership with Virbac, which aims to leverage its global presence to increase product accessibility.

Virbac's CEO, Paul Martingell, highlighted the company's dedication to advancing animal health and addressing unmet needs by integrating specialty products like Thyronorm. With its proven track record, Virbac continues to invest in sustainable growth, enhancing care for senior cats worldwide.